WS #15145
Holding: newest synthesis is 3d 3h old
Eli Lilly's experimental amylin-Zepbound combo (EloraTZP) has demonstrated a 23.3% weight loss in Phase 2 trials, significantly outperforming Zepbound alone and clearing the 18% hurdle set by Citi. This clinical success reinforces Lilly's dominance in the obesity market, though the stock's muted reaction suggests the market may have already priced in the positive data.
Eli Lilly Weight Loss Drug Success
Eli Lilly's experimental amylin-Zepbound combo (EloraTZP) has demonstrated a 23.3% weight loss in Phase 2 trials, significantly outperforming Zepbound alone and clearing the 18% hurdle set by Citi. This clinical success reinforces Lilly's dominance in the obesity market, though the stock's muted reaction suggests the market may have already priced in the positive data.